Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM

AIDS

Volumn 29, Issue 14, 2015, Pages 1855-1862

  Phillips, Andrew N ^a   Cambiano, Valentina ^a   Miners, Alec ^b   Lampe, Fiona C ^a   Rodger, Alison ^a   Nakagawa, Fumiyo ^a   Brown, Alison ^c   Gill, O Noel ^c   De Angelis, Daniela ^c   Elford, Jonathan ^d   Hart, Graham ^a   Johnson, Anne M ^a   Lundgren, Jens D ^e   Collins, Simon ^f   Delpech, Valerie ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d CITY UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f 107 the Maltings   (United Kingdom)

Author keywords

Cost effectiveness; Economic evaluation; HIV; HIV diagnosis; Mathematical models; Prevention; Testing

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONDOM USE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE POLICY; HETEROSEXUALITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; RISK REDUCTION; SEXUAL BEHAVIOR; SIMULATION; UNITED KINGDOM; VIRUS INHIBITION; VIRUS LOAD; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; ECONOMICS; GREAT BRITAIN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MALE HOMOSEXUALITY; MIDDLE AGED; PROCEDURES; TIME FACTOR; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; GREAT BRITAIN; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84975114135     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000767     Document Type: Article

References (34)

1. Beyrer C, Baral SD, van Griensven F, Goodreau SM, Chariyalertsak S, Wirtz AAL, Brookmeyer R. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012; 380:367-377.
2. Cambiano V, O'Connor J, Phillips AN, Rodger A, Lodwick R, Pharris A, et al. Antiretroviral therapy for prevention of HIV transmission: implications for Europe. Euro Surveill 2013; 18.
3. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Prins M, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008; 22:1071-1077.
4. van Sighem A, Jansen I, Bezemer D, De Wolf F, Prins M, Stolte I, Fraser C. Increasing sexual risk behaviour among Dutch men who have sex with men: mathematical models versus prospective cohort data. AIDS 2012; 26:1837-1843.
5. Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. Plos Med 2012; 9:e1001231.
6. Birrell PJ, Gill ON, Delpech VC, Brown A, Desai S, Chadborn T, et al. HIV incidence in men who have sex with men in England and Wales 2001-10: A nationwide population study. Lancet Infect Dis 2013; 13:313-318.
7. Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: Analysis of an extensively documented epidemic. Plos One 2013; 8.
8. Shelton JD. ARVs as HIV prevention: A tough road to wide impact. Science 2011; 334:1645-1646.
9. Rodger A, Bruun T, Cambiano V, Lundgren J, et al. HIV transmission risk through condomless sex if HIV partner on suppressive ART: PARTNER study. Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, 3-6 March [Abstract153LB].
10. Fisher M, Pao D, Murphy G, Dean G, McElborough D, Homer G, Parry JV. Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. AIDS 2007; 21:2309-2314.
11. Brenner B, Wainberg MA, Roger M. Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS 2013; 27:1045-1057.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 25 May 2014].
13. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al., BHIVA Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Update November 2013). HIV Med 2014; 15 (Suppl1):1-85.
14. Collins S, Geffen N. Community views: balancing the public health benefits of earlier antiretroviral treatment with the implications for individual patients - perspectives from the community. Curr Opin HIV AIDS 2014; 9:4-10.
15. Danel C, Gabillard D, Le Carrou J, Anglaret X, Moh R, Eholie S. Early ART and IPT in HV-infected African adults with high CD4 count (Temprano trial). 2015 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA; 2015 [abstract115LB].
16. NAM-EATG. Community consensus statement on the use of antiretroviral therapy in preventing HIV transmission. http://www.hivt4p.org/.
17. Brown AE, Gill ON, Delpech VC. HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care? HIV Med 2013; 14:563-570.
18. Public Health England. HIV in the United Kingdom: 2013 report. Public Health England 2013 November. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317140300680. [cited 13 April 2014].
19. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. http://www.nice.org.uk/article/PMG9/chapter/Foreword. [Accessed 7 September 2014].
20. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335-343.
21. Rodger A, Phillips AN, Speakman A, Gilson R, Fisher M, Wilkins E, et al. Attitudes of people in the UK with HIV who are antiretroviral (ART) naïve to starting ART at high CD4 counts for potential health benefit or to prevent HIV transmission. Plos One 2014.
22. McOwan A. HIV testing: new technologies and new strategies for those at higher risk. Third Joint Conference of BHIVA with BASHH, Liverpool, April 2014.
23. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and Antiretroviral Therapy in San Francisco. Science 2000; 287:650-654.
24. Sood N, Wagner Z, Jaycocks A, Drabo E, Vardavas R. Test-Andtreat in Los Angeles: A mathematical model of the effects of test-And-Treat for the population of men who have sex with men in Los Angeles county. Clin Infect Dis 2013; 56:1789- 1796.
25. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis 2011; 52:1046-1049.
26. Punyacharoensin N, Edmunds WJ, DeAngelis D, et al. Modelling the HIV epidemic among MSM in the United Kingdom: quantifying the contributions to HIV transmission to better inform prevention initiatives. AIDS 2015; 29:339-349.
27. Lorenc T, Marrero-Guillamon I, Aggleton P, Cooper C, Llewellyn A, Lehmann A, et al. Promoting the uptake of HIV testing among men who have sex with men: systematic review of effectiveness and cost-effectiveness. Sex Transm Infect 2011; 87:272-278.
28. Wang SH, Moss JR, Hiller JE. Cost-effectiveness of HIV voluntary counseling and testing in China. Asia-Pacific J Public Health 2011; 23:620-633.
29. Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS 2011; 25:1779-1787.
30. Han XX, Xu JJ, Chu ZX, Chu Z, Dai D, Dai D, et al. Screening acute HIV infections among Chinese men who have sex with men from voluntary counseling and testing centers. Plos One 2011; 6:e28792.
31. Lasry A, Sansom SL, Hicks KA, Uzunangelov V. Allocating HIV prevention funds in the United States: Recommendations from an optimization model. Plos One 2012; 7:e37545.
32. Li JH, Gilmour S, Zhang HQ, Koyanagi A, Shibuya K. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs. AIDS 2012; 26:2069-2078.
33. Long EF, Mandalia R, Mandalia S, Alistar SS, Beck EJ, Brandeau ML. Expanded HIV testing in low-prevalence, high-income countries: A cost-effectiveness analysis for the United Kingdom. Plos One 2014; 9:e95735.
34. Walensky RP, Sax PE, Nakamura YM, Weinstein M, Pel P, Freedberg K, et al. Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013; 158:84-92.